Current:Home > InvestAn experimental Alzheimer's drug outperforms one just approved by the FDA-DB Wealth Institute B2 Expert Reviews
An experimental Alzheimer's drug outperforms one just approved by the FDA
View Date:2024-12-23 15:22:10
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (39697)
Related
- Hurricane-damaged Tropicana Field can be fixed for about $55M in time for 2026 season, per report
- Huge rocket motors arrive at Los Angeles museum for space shuttle Endeavour display
- Trick-or-treat: Snag yourself a pair of chocolate bar-themed Crocs just in time for Halloween
- Chef Michael Chiarello's fatal allergic reaction reveals allergies’ hidden dangers
- Massachusetts lawmakers to consider a soccer stadium for the New England Revolution
- 'Anointed liquidator': How Florida man's Home Depot theft ring led to $1.4M loss, prosecutors say
- Horoscopes Today, October 10, 2023
- Morgan State University plans to build a wall around campus after shooting during homecoming week
- More human remains from Philadelphia’s 1985 MOVE bombing have been found at a museum
- Morgan State University plans to build wall around campus after homecoming week shooting
Ranking
- Investigation into Chinese hacking reveals ‘broad and significant’ spying effort, FBI says
- Australia in talks with Indonesia about a possible challenge to Saudi Arabia for the 2034 World Cup
- To run or not to run? New California senator faces tough decision on whether to enter 2024 campaign
- Scientists winkle a secret from the `Mona Lisa’ about how Leonardo painted the masterpiece
- Robert F. Kennedy Jr. has a long record of promoting anti-vaccine views
- Family Dollar issues huge recall for over-the-counter drugs, medical devices in 23 states
- Man, 19, pleads guilty to third-degree murder in death of teen shot in Pittsburgh school van
- Deion Sanders says Travis Hunter, Colorado's two-way star, cleared to return with protection
Recommendation
-
Bo the police K-9, who located child taken at knifepoint, wins Hero Dog Awards 2024
-
The Machine: Diamondbacks rookie Corbin Carroll playing beyond his years in MLB playoffs
-
New national wildlife refuges in Tennessee, Wyoming created to protect toads, bats, salamanders
-
Cruises detouring away from war-torn Israel
-
Donna Kelce Includes Sweet Nod to Taylor Swift During Today Appearance With Craig Melvin
-
Utah lawsuit says TikTok intentionally lures children into addictive, harmful behavior
-
Israel strikes neighborhood after neighborhood in Gaza as war appears set to escalate
-
One sister survived cancer. Five years later, the other one is still processing it